Merck and Ridgeback's molnupiravir, an oral COVID-19 antiviral medicine, receives first authorization in the world

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization in the United Kingdom (U.K.) for molnupiravir (MK-4482, EIDD-2801), the first oral antiviral medicine authorized for the treatment of mild-to-moderate COVID-19 in adults with a positive SARS-CoV-2 diagnostic test and who have at least one risk factor for developing severe illness.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Merck Business and Industry Source Type: news